ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NIH Inquiry Finds No Impropriety In Treatment of Teddy DeVita

April 9, 1976

Human Protein Index Stirs NCI, NCAB Interest, Fires Up Growing Controversy

August 7, 1981

Large, Conclusive Trials Provide Answers To Treatment Questions For GI Cancers

June 26, 2009

Also M.D. Anderson awarded three new, one renewal SPORE grant.

October 31, 2003

FDA Approves Avastin For Recurrent NSCLC

October 27, 2006

Year 2000 Objectives In Health On Track

June 25, 1999